Figure 1
Figure 1. FcγRIIA can induce active systemic anaphylaxis. (A) Representative histogram plots of human FcR expression on human blood neutrophils. (B) Representative histogram plots of anti-FLAG mAb (top panel) or preformed mouse polyclonal IgG-immune complexes (bottom panel) binding to CHO transfectants expressing the indicated FLAG-tagged human polymorphic variants of FcγRIIA (H131 or R131) and FcγRIIIB (NA1, NA2, or SH). (C) Representative expression of FcγRIIA on blood and peritoneal cells from 3KOIIA mice (open histograms) or nontransgenic 3KO littermate controls (filled histograms): T cells (CD3+), B cells (CD19+), NK cells (DX5+/NK1.1+), neutrophils (Gr1hi/CD11b+), eosinophils (Gr1int/SiglecF+), basophils (IgE+/DX5+), and monocytes/macrophages (CD11b+/Gr1−). (D) Representative expression of FcγRIIA (open histograms) on human blood cells: T cells (CD3+), B cells (CD19+), NK cells (CD56+), neutrophils (CD24+), eosinophils (CCR3+/CDw125+), basophils (FcϵRI+/CD203c+), and monocytes (CD14+); or isotype control (closed histograms). (E-G) Indicated mice were immunized with BSA, (E) in Freunds adjuvant, or (F-G) in alum, challenged with BSA and central temperatures and survival rates were monitored. (E) ASA in FcRγ−/− (n = 7) and FcRγ−/−IIA mice (n = 5). (F) ASA in FcRγ−/− (n = 4) and FcRγ−/−IIA (n = 5) mice. (G) ASA in FcRγ−/−IIA mice injected twice with anti-FcγRIIA mAb IV.3 (n = 5) or not (n = 6), before BSA-challenge. FcRγ−/− mice were used as controls (n = 7). (E-G) Data are represented as mean ± SEM. (A-G) Data are representative of at least 2 independent experiments (*P < .05; **P < .01; ***P < .001).

FcγRIIA can induce active systemic anaphylaxis. (A) Representative histogram plots of human FcR expression on human blood neutrophils. (B) Representative histogram plots of anti-FLAG mAb (top panel) or preformed mouse polyclonal IgG-immune complexes (bottom panel) binding to CHO transfectants expressing the indicated FLAG-tagged human polymorphic variants of FcγRIIA (H131 or R131) and FcγRIIIB (NA1, NA2, or SH). (C) Representative expression of FcγRIIA on blood and peritoneal cells from 3KOIIA mice (open histograms) or nontransgenic 3KO littermate controls (filled histograms): T cells (CD3+), B cells (CD19+), NK cells (DX5+/NK1.1+), neutrophils (Gr1hi/CD11b+), eosinophils (Gr1int/SiglecF+), basophils (IgE+/DX5+), and monocytes/macrophages (CD11b+/Gr1). (D) Representative expression of FcγRIIA (open histograms) on human blood cells: T cells (CD3+), B cells (CD19+), NK cells (CD56+), neutrophils (CD24+), eosinophils (CCR3+/CDw125+), basophils (FcϵRI+/CD203c+), and monocytes (CD14+); or isotype control (closed histograms). (E-G) Indicated mice were immunized with BSA, (E) in Freunds adjuvant, or (F-G) in alum, challenged with BSA and central temperatures and survival rates were monitored. (E) ASA in FcRγ−/− (n = 7) and FcRγ−/−IIA mice (n = 5). (F) ASA in FcRγ−/− (n = 4) and FcRγ−/−IIA (n = 5) mice. (G) ASA in FcRγ−/−IIA mice injected twice with anti-FcγRIIA mAb IV.3 (n = 5) or not (n = 6), before BSA-challenge. FcRγ−/− mice were used as controls (n = 7). (E-G) Data are represented as mean ± SEM. (A-G) Data are representative of at least 2 independent experiments (*P < .05; **P < .01; ***P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal